OraSure Technologies Inc (OraSure) develops, manufactures, and distributes oral fluid diagnostic, collection devices and other diagnostic products for detection and diagnosis of critical medical conditions. Its product portfolio encompasses around infectious disease tests for the detection of antibodies for the HIV and Hepatitis C virus; Ebola virus, Zika virus and antigens for influenza type A and type B. OraSure also sells immunoassay tests and reagents for insurance risk assessment, substance-abuse testing and forensic toxicology applications; and products for the cryosurgical removal of warts and several other benign skin lesions. The company distributes its products to hospitals, clinics, community-based organizations and other public health organizations, distributors, clinical laboratories, and commercial and industrial entities. The company sells its products through distributors in the Americas, Europe, and Asia-Pacific region. OraSure is headquartered in Bethlehem, Pennsylvania, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company OraSure Technologies Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- OraSure Technologies Inc Company Overview
- OraSure Technologies Inc Company Snapshot
- OraSure Technologies Inc Pipeline Products and Ongoing Clinical Trials Overview
- OraSure Technologies Inc - Pipeline Analysis Overview
- Business Description
- OraSure Technologies Inc - Key Facts
- OraSure Technologies Inc - Major Products and Services
- OraSure Technologies Inc Pipeline Products by Development Stage
- OraSure Technologies Inc Pipeline Products Overview
- In-home Self-Test - Pan-SARS-Coronavirus
- In-home Self-Test - Pan-SARS-Coronavirus Product Overview
- InteliSwab COVID-19 Rapid Test - OTC
- InteliSwab COVID-19 Rapid Test - OTC Product Overview
- InteliSwab COVID-19 Rapid Test Pro
- InteliSwab COVID-19 Rapid Test Pro Product Overview
- InteliSwab COVID-19 Rapid Test Rx
- InteliSwab COVID-19 Rapid Test Rx Product Overview
- Intercept i2 he
- Intercept i2 he Product Overview
- Next-Generation Colli-Pee
- Next-Generation Colli-Pee Product Overview
- Oral Fluid Antibody ELISA Test - COVID-19
- Oral Fluid Antibody ELISA Test - COVID-19 Product Overview
- OraQuick Coronavirus Rapid Antigen Self-Test - OTC
- OraQuick Coronavirus Rapid Antigen Self-Test - OTC Product Overview
- OraQuick Coronavirus Rapid Antigen Self-Test - Prescription Use
- OraQuick Coronavirus Rapid Antigen Self-Test - Prescription Use Product Overview
- OraQuick Coronavirus Rapid Antigen Self-Test - Professional Use
- OraQuick Coronavirus Rapid Antigen Self-Test - Professional Use Product Overview
- OraQuick Rapid Test - Zika Virus
- OraQuick Rapid Test - Zika Virus Product Overview
- OraSure Oral Antibody Collection Device
- OraSure Oral Antibody Collection Device Product Overview
- Second Generation OraQuick Ebola Rapid Antigen Test
- Second Generation OraQuick Ebola Rapid Antigen Test Product Overview
- Surequick
- Surequick Product Overview
- Suresight
- Suresight Product Overview
- VAX-ID
- VAX-ID Product Overview
- OraSure Technologies Inc - Key Competitors
- OraSure Technologies Inc - Key Employees
- OraSure Technologies Inc - Key Employee Biographies
- OraSure Technologies Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- OraSure Technologies Inc, Recent Developments
- May 10, 2023: OraSure Reports 1Q23 record revenue of $155.0 million announces new collaborations as company increasingly focuses on core growth
- Nov 08, 2022: OraSure Reports 3Q22 Record Revenue of $116.5 Million Growing 116% Year-Over-Year
- Aug 09, 2022: OraSure Reports 2Q22 Record Revenue of $80.2 Million Growing 39% Year-Over-Year
- Jul 28, 2022: OraSure’s ongoing commitment to end the hepatitis C epidemic heats up at the racetrack
- Jul 14, 2022: OraSure Technologies launches new product for microbiome researchers to study DNA and RNA
- May 10, 2022: OraSure Reports 1Q22 Record Revenue of $67.7 Million +16% Year-Over-Year With 21% Growth in Non-COVID Revenue
- Mar 22, 2022: OraSure Director Nancy Gagliano Selected to Serve as Interim Chief Executive Officer; Brings Extensive Diagnostics and Healthcare Leadership Experience to Role
- Feb 23, 2022: Orasure Technologies Reports 4q21 Revenue of $63.6 Million; Inteliswab® Production Scales Up
- Nov 30, 2021: OraSure Technologies remains committed to the global fight against HIV 40 Years After the Discovery of the HIV Virus
- Nov 03, 2021: OraSure Technologies Reports 3Q21 Revenue of $53.9 Million
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- OraSure Technologies Inc Pipeline Products and Ongoing Clinical Trials Overview
- OraSure Technologies Inc Pipeline Products by Equipment Type
- OraSure Technologies Inc Pipeline Products by Indication
- OraSure Technologies Inc, Key Facts
- OraSure Technologies Inc, Major Products and Services
- OraSure Technologies Inc Number of Pipeline Products by Development Stage
- OraSure Technologies Inc Pipeline Products Summary by Development Stage
- In-home Self-Test - Pan-SARS-Coronavirus - Product Status
- In-home Self-Test - Pan-SARS-Coronavirus - Product Description
- InteliSwab COVID-19 Rapid Test - OTC - Product Status
- InteliSwab COVID-19 Rapid Test - OTC - Product Description
- InteliSwab COVID-19 Rapid Test Pro - Product Status
- InteliSwab COVID-19 Rapid Test Pro - Product Description
- InteliSwab COVID-19 Rapid Test Rx - Product Status
- InteliSwab COVID-19 Rapid Test Rx - Product Description
- Intercept i2 he - Product Status
- Intercept i2 he - Product Description
- Next-Generation Colli-Pee - Product Status
- Next-Generation Colli-Pee - Product Description
- Oral Fluid Antibody ELISA Test - COVID-19 - Product Status
- Oral Fluid Antibody ELISA Test - COVID-19 - Product Description
- OraQuick Coronavirus Rapid Antigen Self-Test - OTC - Product Status
- OraQuick Coronavirus Rapid Antigen Self-Test - OTC - Product Description
- OraQuick Coronavirus Rapid Antigen Self-Test - Prescription Use - Product Status
- OraQuick Coronavirus Rapid Antigen Self-Test - Prescription Use - Product Description
- OraQuick Coronavirus Rapid Antigen Self-Test - Professional Use - Product Status
- OraQuick Coronavirus Rapid Antigen Self-Test - Professional Use - Product Description
- OraQuick Rapid Test - Zika Virus - Product Status
- OraQuick Rapid Test - Zika Virus - Product Description
- OraSure Oral Antibody Collection Device - Product Status
- OraSure Oral Antibody Collection Device - Product Description
- Second Generation OraQuick Ebola Rapid Antigen Test - Product Status
- Second Generation OraQuick Ebola Rapid Antigen Test - Product Description
- Surequick - Product Status
- Surequick - Product Description
- Suresight - Product Status
- Suresight - Product Description
- VAX-ID - Product Status
- VAX-ID - Product Description
- OraSure Technologies Inc, Key Employees
- OraSure Technologies Inc, Key Employee Biographies
- OraSure Technologies Inc, Other Locations
- OraSure Technologies Inc, Subsidiaries
- Glossary
- OraSure Technologies Inc Pipeline Products by Equipment Type
- OraSure Technologies Inc Pipeline Products by Development Stage
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Maxim Biomedical Inc
- Nymox Pharmaceutical Corp
- Trinity Biotech Plc
- Zoetis Inc
- Psychemedics Corp
- MedMira Inc
